Medications transforming the world of weight loss could have an unexpected secondary benefit:
Protecting the brain from age-related decline.
A growing body of evidence suggests that GLP-1 agonists like semaglutide and tirzepatide may be associated with reductions in dementia risk.
What the Research Indicates
A large 2025 cohort study tracking over 60,000 adults with type 2 diabetes and obesity found that patients who started semaglutide or tirzepatide had a 37% lower risk of developing dementia compared to those who didn’t. The study followed patients for up to seven years and also found reduced rates of stroke and all-cause mortality.
A separate analysis of roughly 200,000 veterans reached similar conclusions: GLP-1 medications were associated with lower rates of neurocognitive disorders, including Alzheimer’s disease.
Why Would a Diabetes Medication Protect the Brain?
The connection isn’t as surprising as it might sound.
Alzheimer’s is sometimes informally called “Type 3 Diabetes” by researchers—a reference to the fact that insulin resistance in the brain seems to play a significant role in the disease’s development. Neurons depend on insulin signaling to function properly; and when that signaling breaks down, it may accelerate the accumulation of amyloid plaques and tau tangles, the hallmark damage of Alzheimer’s.
GLP-1 agonists work by mimicking a gut hormone that stimulates insulin release and regulates blood sugar. But GLP-1 receptors aren’t only found in the gut. They’re also expressed throughout the brain, including within regions that are critical to memory and cognition.
Research has uncovered several potential neuroprotective mechanisms:
Reducing neuroinflammation. Chronic brain inflammation is a key driver of Alzheimer’s progression. Studies show semaglutide promotes a shift in microglia—the brain’s immune cells—from an inflammatory state to a protective, anti-inflammatory one.
Clearing amyloid and tau. In some models of Alzheimer’s, semaglutide treatment was associated with reduced amyloid-beta plaque deposition and fewer tau tangles. These are the two primary pathological changes that define the disease.
Improving brain glucose metabolism. One hallmark of Alzheimer’s is reduced glucose uptake in the brain. GLP-1 medications appear to improve cerebral energy metabolism, potentially slowing neurodegeneration.
Vascular protection. Cardiovascular risk factors—like high blood pressure, atherosclerosis, and obesity—significantly increase Alzheimer’s risk. GLP-1 medications’ well-documented cardiovascular benefits likely contribute to their apparent brain-protective effects, as well.
What Clinical Trials Have Found
Two large Phase 3 trials—EVOKE and EVOKE Plus—tested semaglutide in people already diagnosed with early onset Alzheimer’s. Both trials were completed in January of 2026.
The results from the study were ultimately somewhat disappointing, because semaglutide did not meaningfully slow cognitive decline in people who already had an Alzheimer’s diagnosis.
However…the data contained more nuance than the headlines suggested. Participants taking semaglutide showed reductions of up to 10% in biomarkers associated with Alzheimer’s compared to placebo.
That’s an important distinction. What this means is that these medications may work best as a preventative measure (as opposed to being a treatment for a disease process that’s already underway), allowing for intervention before neurodegeneration has occurred—as opposed to after.
It’s also worth noting that the studies showing reduced dementia risk are mostly utilizing observational data from people taking these medications for metabolic reasons, years before cognitive symptoms would appear.
Important Caveats
The research is promising but not definitive. Many of the studies included patients with type 2 diabetes or obesity—populations that are already at an elevated risk for developing dementia. At this point, it isn’t clear whether the findings will apply equally to people without those conditions.
The EVOKE trial results also highlight that neurodegeneration may be difficult to reverse once it has occurred, regardless of the intervention. This makes prevention a fundamentally different—and potentially more achievable—goal.
Researchers also caution that some of the benefit seen in observational studies might be explained indirectly by weight loss, better blood sugar control, lower blood pressure, or reduced cardiovascular risk, for example. Disentangling those effects from a directly neuroprotective action of the medication itself will require carefully designed trials that are still underway.
The Bottom Line
The evidence is not yet strong enough to prescribe semaglutide or tirzepatide for Alzheimer’s prevention—and no regulatory body has approved them for this purpose. But for people who are already candidates for these medications, the potential brain-protective benefits add another dimension to an already compelling risk-benefit profile.
At Renew Youth, our focus is hormone therapy and longevity medicine—but not to the exclusion of everything else. Would you like to have us in your anti-aging corner? Call us at (800) 859-7511 or use our easy contact form to schedule your complimentary 30-minute consultation.